Levofloxacin prescribing information |
|
 |
|
2010 Jun;19(2):131-4.
Zullo A, De Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan C.
Gastroenterology and Digestive Endoscopy, "Nuovo Regina Margherita" Hospital, Rome, Italy; Email: zullo66@yahoo.it.
Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.
BACKGROUND AND AIMS. A levofloxacin-based triple therapy and a rifabutin-based regimen are advised as second-line and rescue therapies in the current Italian guidelines for H. pylori eradication. However, no data are available for the efficacy of these treatments in clinical practice. METHODS. A total of 86 consecutive patients who failed a standard, first-line, triple therapy for H. pylori infection were treated with a 10-day triple therapy including omeprazole 20 mg, amoxycillin 1 g, and levofloxacin 250 mg or 500 mg, each given twice daily. Eradication failure patients received a 10-day rescue therapy with omeprazole 20 mg, amoxycillin 1 g, and rifabutin 150 mg, each given twice daily. A further therapeutic attempt was performed with a 14-day, high-dose dual therapy (esomeprazole 40 mg and amoxicillin 1 g, each thrice daily). RESULTS. Following the second-line therapy, H. pylori infection was cured in 76.4% (95% CI = 67.8-85.0) and 79.5% (95% CI = 70.8-88.2) at intention-to-treat (ITT) and per-protocol (PP) analysis, respectively. After the rescue therapy, bacterial eradication was achieved in 84.6% (95% CI = 65-100). Two patients with persistent infection were successfully cured with the high-dose dual therapy. CONCLUSION. The efficacy of levofloxacin-based second-line therapy seems to be decreasing, whilst rescue therapy with rifabutin would appear a valid third-line therapy, and a high-dose dual therapy may be used as a further rescue therapy.
2010 Jun 30. [Epub ahead of print]
Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S.
Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Anti-Infectives and the Risk of Severe Hypoglycemia in Users of Glipizide or Glyburide.
2010 Jul;23(3):245-249.
Iffat W, Shoaib MH, Muhammad IN, Rehana, Tasleem S, Gauhar S.
Dow College of Pharmacy, Dow Medical University, Karachi.
Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates.
2010 Jun;22(3):153-9.
Tempera G, Furneri PM, Carlone NA, Cocuzza C, Rigoli R, Musumeci R, Pilloni AP, Prenna M, Tufano MA, Tullio V, Vitali LA, Nicoletti G.
Department of Microbiological and Gynecological Sciences, University of Catania, Italy. tempera@unict.it
Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren.
2010 Apr-Jun;53(2):276-80.
Ramakrishnan R, Ramesh S, Bharathi MJ, Amuthan M, Viswanathan S.
Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu- 627 001, India.
Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
2009 Nov 17;89(42):2983-7.
Sun HL, Yang QW, Xu YC, Wang H, Xie XL, Chen MJ, Zhang XZ, Liu Y, Ye HF, Sun ZY, Duan Q, Ni YX, Yu YS, Zhao WS, He L, Wang J, Ji P, Liu PP, Zhang LX.
Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
[Resistance study of community respiratory pathogens isolated in China from 2005 to 2007] [Article in Chinese]
2009 Nov 5;3(11):843-8.
Moehario LH, Tjoa E, Kiranasari A, Ningsih I, Rosana Y, Karuniawati A.
Department of Microbiology, Faculty of Medicine University of Indonesia. Indonesia. luckyhmoehario@gmail.com
Trends in antimicrobial susceptibility of gram-negative bacteria isolated from blood in Jakarta from 2002 to 2008.
2009 Oct;62(5):452-9.
Kashimoto Y, Kurosaka Y, Karibe Y, Uoyama S, Fujikawa K, Namba K, Otani T, Yamaguchi K.
Daiichi Sankyo Co. Ltd., Biological Research Laboratories IV.
[Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice] [Article in Japanese]
2009 Dec;21(12):722-5.
Gao XL, Liu B, Jin K, Cheng J, Li JB, Zhou SS.
Intensive Care Unit, Anhui Province Hospital, Affiliated to Anhui Medical University, Hefei 230032, Anhui, China.
[A study on the active efflux system in methicillin-resistant Staphylococcus aureus] [Article in Chinese]
2009 Jul 28. [Epub ahead of print]
Inoshita A, Yokoi H, Matsumoto F, Yao T, Kawano K, Furukawa M, Ikeda K.
Department of Otorhinolaryngology, Juntendo University School of Medicine, Tokyo, Japan.
A randomized prospective study of oral levofloxacin vs intravenous flomoxef prophylaxis in postoperative infection after endoscopic sinus surgery.
2008 May;19(3):243-9.
Zhanel GG, Decorby M, Nichol KA, Baudry PJ, Karlowsky JA, Lagace-Wiens PR, McCracken M, Mulvey MR, Hoban DJ.
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba.
Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit
2008 Oct;20 Suppl 1:28-35.
Dartois N, Castaing N, Gandjini H, Cooper A; Tigecycline 313 Study Group.
Wyeth Research, Paris, France. dartoin@wyeth.com
Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience.
2008 Oct;4(5):843-53.
McGregor JC, Allen GP, Bearden DT.
Oregon State University College of Pharmacy, Portland, OR, USA.
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis.
2008 Oct;42(10):758-61.
Shen JL, Yang BW, Zhi S, Cui SH, Xi ML, Yang PF, Meng JH.
College of Food Science and Engineering, Northwest Agriculture and Forestry University, Yangling Shaanxi 712100, China.
[Detection and analysis of antibiotic resistance of Salmonella from retail meats in some districts of Shaanxi province] [Article in Chinese]
2008 Dec;13(6):572-6.
Sanches B, Coelho L, Moretzsohn L, Vieira G Jr.
Instituto Alfa de Gastroenterologia, Universidade Federal de Minas Gerais, Minas Gerais, Brazil.
Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.
2007;52(1-2):10-7.
Malakhova MV, Vereshchagin VA, Il'ina EN, Govorun VM, Filimonova OIu, Grudinina SA, Sidorenko SV.
[MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones] [Article in Russian]
2007 Oct;23(5):349-51.
Zhang LQ, Su F, Liu HY, Wu XT, Zhao HT.
Department of Burns and Plastic Surgery, Weifang People's Hospital, PR China.
[Survey on the distribution of burn pathogens and their antibiotic resistance in burn unit] [Article in Chinese]
2007 Jun;3(2):309-17.
Giordano P, Weber K, Gesin G, Kubert J.
Skin and skin structure infections: treatment with newer generation fluoroquinolones.
2007;2(4):551-9.
Blasi F, Aliberti S, Tarsia P.
Institute of Respiratory Diseases, University of Milan, IRCCS Fondazione Policlinico-Mangiagalli-Regina Elena Milano, Italy.
Clinical applications of azithromycin microspheres in respiratory tract infections.
2007 Dec;82(12):891-6.
Kazumi Y, Itagaki N, Ohmori M, Wada M, Hoshino H, Mitarai S, Sugawara I, Ishikawa N, Mori T.
Pathology Division, Mycobacterium Reference Center, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo. kazumi@jata.or.jp
[Frequency of MDR-TB/XDR-TB strains isolated from chronic pulmonary tuberculosis patients in Japan] [Article in Japanese]
J Ocul Pharmacol Ther. 2009 Oct;25(5):425-31.
Choi JA, Chung SK.
Department of Ophthalmology and Visual Science, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Safety of intracameral injection of gatifloxacin, levofloxacin on corneal endothelial structure and viability.
PURPOSE: To investigate the safety of intracameral injection of gatifloxacin, levofloxacin in a rabbit model as prophylaxis against endophthalmitis. METHODS: Twenty-four eyes of New Zealand white rabbits were randomly divided into 3 treatment groups: levofloxacin, gatifloxacin, and balanced salt solution (BSS) control groups. After 100 microL of each was injected into the anterior chamber, endothelial toxicity was evaluated by measuring the central corneal thicknesses and the clinical toxicity scores using a slit-lamp at post-procedure days 3 and 7. The percent of dead cells was determined by vital staining with alizarin red and trypan blue at 7 days after injection. Finally, in each group, scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were performed for the evaluation of structural integrity. RESULTS: The toxicity scores were increased at post-procedure days 3 and 7, but the difference among the groups was not statistically significant (P = 0.661, 0.216, respectively). With regard to baseline corneal thickness, only the levofloxacin group exhibited a significant increase from baseline (P = 0.028), whereas the other treatment groups showed no difference from baseline (P = 0.128 in gatifloxacin, 0.161 in BSS group). The mean corneal endothelial damage was 0.81 +/- 0.31% in the levofloxacin group, 0.56 +/- 0.47% in the gatifloxacin group, and 0.53 +/- 0.52% in the BSS group, with no statistically significant difference noted among the groups (P = 0.582). SEM revealed a well-preserved hexagonal endothelial cell mosaic and normal microvilli on the endothelial cell surface in the gatifloxacin and control groups. However, the levofloxacin group showed slightly disintegrated cellular borders. TEM revealed that each group maintained normal intracellular organization, whereas the levofloxacin group exhibited slightly flat cell configuration with irregular folds on the apical cell surface. CONCLUSIONS: Intracameral injection of gatifloxacin and levofloxacin was nontoxic in terms of clinical toxicity score, corneal thickness, and viability. However, there were changes on electron microscopy in the levofloxacin group, which may indicate microstructural damage to corneal endothelial cells.
J Infect Chemother. 2009 Oct;15(5):293-300. Epub 2009 Oct 24.
Zhang J, Xu JF, Liu YB, Xiao ZK, Huang JA, Si B, Sun SH, Xia QM, Wu XJ, Cao GY, Shi YG, Zhang YY.
Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Lu, Shanghai 200040, China.
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
J Infect Chemother. 2009 Oct;15(5):301-11. Epub 2009 Oct 24.
Zhang YY, Huang HH, Ren ZY, Zheng HG, Yu YS, Lü XJ, Xiao ZK, Yang HF, Xiu QY, Chen BY, Yue HM, Hao QL, Huang JA, Ma H, Xiao W, Guo DY, Si B, Sun SH, Zhang W, Li QH, Shen HH, Duan J, Li HY, Yao WZ, Gu JM, Xia QM, Ying KJ, Liu A, Yang HP, Shi MH, Sun T
Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Lu, Shanghai 200040, China.
Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
Levofloxacin review article...
|
|
Antibacterial and antiviral agent
 Levofloxacin prescribing information
Buy here
|
|
My Basket
